Extracorporeal Elimination of Piperacillin/Tazobactam during Molecular Adsorbent Recirculating System Therapy

Heather A. Personett, Scott L. Larson, Erin N. Frazee, Scott Nyberg, Ziad M El-Zoghby

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Use of the Molecular Adsorbent Recirculating System (MARS) as a liver support device continues to grow worldwide. Various components of the MARS circuit remove both protein-bound and water-soluble molecules. Little is known about the extent of the enhanced clearance mechanisms used in MARS therapy on drug elimination. Of particular interest to acute care practitioners is the impact of MARS on antibiotic clearance, as suboptimal concentrations of such drugs can negatively impact patient outcomes. The properties of piperacillin/tazobactam suggest that elimination may be enhanced in the setting of MARS therapy. We describe two cases in which this was studied. Piperacillin concentrations were determined at various points within the MARS circuit, and patient serum concentrations were reported throughout the dosing interval while receiving MARS therapy. Piperacillin concentrations in both cases were in excess of the desired goal minimum inhibitory concentrations for treatment of gram-negative infections. Use of an extended-infusion strategy of piperacillin/tazobactam 3.375 or 4.5 g given every 8 hours maintained desired serum levels throughout the dosing interval. To our knowledge, this is the second published report on the use of piperacillin/tazobactam during MARS therapy. These case reports reveal successful dosing strategies for patients requiring piperacillin/tazobactam while receiving MARS therapy, as well as quantify the influence of individual MARS elements on drug extraction.

Original languageEnglish (US)
Pages (from-to)e136-e139
JournalPharmacotherapy
Volume35
Issue number8
DOIs
StatePublished - Aug 1 2015

Fingerprint

Piperacillin
Therapeutics
Microbial Sensitivity Tests
Serum
Pharmaceutical Preparations
tazobactam drug combination piperacillin
Anti-Bacterial Agents
Drug Therapy
Equipment and Supplies
Water
Liver
Infection
Proteins

Keywords

  • acute liver failure
  • albumin dialysis
  • Molecular Adsorbent Recirculating System
  • molecular adsorbent recirculating system therapy
  • pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Extracorporeal Elimination of Piperacillin/Tazobactam during Molecular Adsorbent Recirculating System Therapy. / Personett, Heather A.; Larson, Scott L.; Frazee, Erin N.; Nyberg, Scott; El-Zoghby, Ziad M.

In: Pharmacotherapy, Vol. 35, No. 8, 01.08.2015, p. e136-e139.

Research output: Contribution to journalArticle

Personett, Heather A. ; Larson, Scott L. ; Frazee, Erin N. ; Nyberg, Scott ; El-Zoghby, Ziad M. / Extracorporeal Elimination of Piperacillin/Tazobactam during Molecular Adsorbent Recirculating System Therapy. In: Pharmacotherapy. 2015 ; Vol. 35, No. 8. pp. e136-e139.
@article{c4861909843f464f871756444e79189a,
title = "Extracorporeal Elimination of Piperacillin/Tazobactam during Molecular Adsorbent Recirculating System Therapy",
abstract = "Use of the Molecular Adsorbent Recirculating System (MARS) as a liver support device continues to grow worldwide. Various components of the MARS circuit remove both protein-bound and water-soluble molecules. Little is known about the extent of the enhanced clearance mechanisms used in MARS therapy on drug elimination. Of particular interest to acute care practitioners is the impact of MARS on antibiotic clearance, as suboptimal concentrations of such drugs can negatively impact patient outcomes. The properties of piperacillin/tazobactam suggest that elimination may be enhanced in the setting of MARS therapy. We describe two cases in which this was studied. Piperacillin concentrations were determined at various points within the MARS circuit, and patient serum concentrations were reported throughout the dosing interval while receiving MARS therapy. Piperacillin concentrations in both cases were in excess of the desired goal minimum inhibitory concentrations for treatment of gram-negative infections. Use of an extended-infusion strategy of piperacillin/tazobactam 3.375 or 4.5 g given every 8 hours maintained desired serum levels throughout the dosing interval. To our knowledge, this is the second published report on the use of piperacillin/tazobactam during MARS therapy. These case reports reveal successful dosing strategies for patients requiring piperacillin/tazobactam while receiving MARS therapy, as well as quantify the influence of individual MARS elements on drug extraction.",
keywords = "acute liver failure, albumin dialysis, Molecular Adsorbent Recirculating System, molecular adsorbent recirculating system therapy, pharmacokinetics",
author = "Personett, {Heather A.} and Larson, {Scott L.} and Frazee, {Erin N.} and Scott Nyberg and El-Zoghby, {Ziad M}",
year = "2015",
month = "8",
day = "1",
doi = "10.1002/phar.1618",
language = "English (US)",
volume = "35",
pages = "e136--e139",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "8",

}

TY - JOUR

T1 - Extracorporeal Elimination of Piperacillin/Tazobactam during Molecular Adsorbent Recirculating System Therapy

AU - Personett, Heather A.

AU - Larson, Scott L.

AU - Frazee, Erin N.

AU - Nyberg, Scott

AU - El-Zoghby, Ziad M

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Use of the Molecular Adsorbent Recirculating System (MARS) as a liver support device continues to grow worldwide. Various components of the MARS circuit remove both protein-bound and water-soluble molecules. Little is known about the extent of the enhanced clearance mechanisms used in MARS therapy on drug elimination. Of particular interest to acute care practitioners is the impact of MARS on antibiotic clearance, as suboptimal concentrations of such drugs can negatively impact patient outcomes. The properties of piperacillin/tazobactam suggest that elimination may be enhanced in the setting of MARS therapy. We describe two cases in which this was studied. Piperacillin concentrations were determined at various points within the MARS circuit, and patient serum concentrations were reported throughout the dosing interval while receiving MARS therapy. Piperacillin concentrations in both cases were in excess of the desired goal minimum inhibitory concentrations for treatment of gram-negative infections. Use of an extended-infusion strategy of piperacillin/tazobactam 3.375 or 4.5 g given every 8 hours maintained desired serum levels throughout the dosing interval. To our knowledge, this is the second published report on the use of piperacillin/tazobactam during MARS therapy. These case reports reveal successful dosing strategies for patients requiring piperacillin/tazobactam while receiving MARS therapy, as well as quantify the influence of individual MARS elements on drug extraction.

AB - Use of the Molecular Adsorbent Recirculating System (MARS) as a liver support device continues to grow worldwide. Various components of the MARS circuit remove both protein-bound and water-soluble molecules. Little is known about the extent of the enhanced clearance mechanisms used in MARS therapy on drug elimination. Of particular interest to acute care practitioners is the impact of MARS on antibiotic clearance, as suboptimal concentrations of such drugs can negatively impact patient outcomes. The properties of piperacillin/tazobactam suggest that elimination may be enhanced in the setting of MARS therapy. We describe two cases in which this was studied. Piperacillin concentrations were determined at various points within the MARS circuit, and patient serum concentrations were reported throughout the dosing interval while receiving MARS therapy. Piperacillin concentrations in both cases were in excess of the desired goal minimum inhibitory concentrations for treatment of gram-negative infections. Use of an extended-infusion strategy of piperacillin/tazobactam 3.375 or 4.5 g given every 8 hours maintained desired serum levels throughout the dosing interval. To our knowledge, this is the second published report on the use of piperacillin/tazobactam during MARS therapy. These case reports reveal successful dosing strategies for patients requiring piperacillin/tazobactam while receiving MARS therapy, as well as quantify the influence of individual MARS elements on drug extraction.

KW - acute liver failure

KW - albumin dialysis

KW - Molecular Adsorbent Recirculating System

KW - molecular adsorbent recirculating system therapy

KW - pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=84939481886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939481886&partnerID=8YFLogxK

U2 - 10.1002/phar.1618

DO - 10.1002/phar.1618

M3 - Article

C2 - 26289310

AN - SCOPUS:84939481886

VL - 35

SP - e136-e139

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 8

ER -